Mesoblast Hits US$30M Ryoncil Sales in Q3 as Cumulative Revenue Nears US$100M
Mesoblast posts US$30.3 million Ryoncil revenue in March quarter
Mesoblast Limited (ASX: MSB) has reported Mesoblast Ryoncil Revenue Reaches US$30M for the quarter ended 31 March 2026, bringing cumulative sales since launch to nearly US$100 million. Strong sales in February and March offset typical January holiday seasonality, demonstrating sustained commercial traction for the first FDA-approved mesenchymal stromal cell therapy.
The revenue milestone strengthens the company’s balance sheet and directly funds label extension studies and late-stage pipeline programmes without the need for dilutive capital raises. Ryoncil remains the only FDA-approved treatment for children under 12 with steroid-refractory acute graft-versus-host disease.
When big ASX news breaks, our subscribers know first
What is Ryoncil and why does FDA approval matter?
Ryoncil (remestemcel-L-rknd) is an allogeneic mesenchymal stromal cell therapy, meaning it is manufactured from donor cells and can be used “off-the-shelf” without requiring a patient-specific cell source. The therapy is approved for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGvHD) in paediatric patients aged 2 months and older.
SR-aGvHD is a life-threatening complication that can occur after bone marrow or stem cell transplants. It happens when donor immune cells attack the recipient’s tissues, and standard steroid treatments fail to control the inflammatory response. Without effective intervention, mortality rates are high.
Ryoncil’s FDA approval in 2025 marked a regulatory milestone as the first mesenchymal stromal cell product approved by the agency for any indication. This approval established a precedent for the clinical use of allogeneic cell therapies, validating both the manufacturing process and the therapeutic mechanism across a range of inflammatory conditions. For investors, this first-mover regulatory status creates a commercial moat and de-risks the broader technology platform for future indications.
Revenue trajectory strengthens the investment case
The US$30.3 million in Q3 FY26 net sales reflects consistent commercial execution during the first full year of Ryoncil’s market launch. Management noted that strong February and March performance offset typical January softness associated with holiday seasonality, a pattern that demonstrates underlying demand stability.
Dr Silviu Itescu, Chief Executive
“Revenue for Ryoncil continues to be impressive. We will outline our growth strategy for Ryoncil as well as our robust late-stage product pipeline at our inaugural R&D event this week.”
Ryoncil revenue is now directly funding label extension trials and late-stage clinical programmes, reducing reliance on external financing. This self-funding capability differentiates Mesoblast from pre-revenue ASX biotech peers and supports pipeline development without shareholder dilution.
The company will host its inaugural R&D Day on Wednesday, 8 April 2026 in New York City, webcast live from 8:00am to 11:00am EST. The event will feature presentations from senior leadership and key opinion leaders, providing investors with detailed strategic guidance on both Ryoncil’s growth trajectory and the broader product pipeline.
| Period | Net Revenue (US$M) | Status |
|---|---|---|
| Q3 FY26 (Jan-Mar 2026) | 30.3 | Strong Feb/Mar offset Jan seasonality |
| Cumulative since launch | Approaching 100.0 | First full year of commercial sales |
The approaching US$100 million cumulative revenue milestone validates commercial viability and positions Mesoblast to scale marketing efforts and expand into additional geographies through existing partnerships.
The next major ASX story will hit our subscribers first
Pipeline expansion and commercial partnerships
Mesoblast is advancing Ryoncil into additional indications and developing a second-generation cell therapy platform for chronic inflammatory conditions. Key pipeline programmes include:
- Ryoncil label extensions: SR-aGvHD in adults and biologic-resistant inflammatory bowel disease
- Rexlemestrocel-L: Heart failure and chronic low back pain
The company has established commercial partnerships in Japan, Europe and China, providing geographic optionality for both Ryoncil and future product candidates. These partnerships enable market access in regions where Mesoblast does not maintain direct commercial infrastructure, reducing capital requirements while preserving revenue participation.
Mesoblast’s intellectual property portfolio comprises over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions, manufacturing methods and therapeutic indications. These patents provide commercial protection extending through to at least 2044 in all major markets, securing long-term exclusivity for the company’s technology platform.
The successful Ryoncil launch de-risks the broader pipeline by validating both the manufacturing process at industrial scale and the regulatory pathway for allogeneic cell therapies. Multiple late-stage programmes now benefit from this established precedent, reducing clinical and regulatory uncertainty for future approvals.
What to watch next
Investors should monitor the following near-term catalysts:
- R&D Day webcast on 8 April 2026 for detailed growth strategy and pipeline updates
- Quarterly revenue trajectory as the primary commercial indicator for Ryoncil market penetration
- Label extension progress for adult SR-aGvHD and inflammatory bowel disease indications
- Late-stage readouts from rexlemestrocel-L programmes in heart failure and chronic low back pain
Mesoblast is transitioning from a clinical-stage to a commercial-stage biotechnology company with multiple growth levers. The combination of recurring Ryoncil revenue, a validated regulatory pathway, and a deep pipeline of late-stage assets creates a differentiated risk/reward profile among ASX biotech peers. The inaugural R&D Day provides an immediate opportunity for management to articulate the commercial roadmap and quantify market opportunity across the expanded product portfolio.
Want the Next Biotech Breakthrough in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at StockWire X to receive biotech and healthcare alerts the moment market-moving announcements hit the ASX.